Abstract
The purpose of our investigation is to compare the radio-enhancement of three imidazole compounds to human oral malignant tumor transplanted on nude mice.Methods and evaluation: Battelle Columbus Laboratories Protocol.Tumor: PNC-1-JCK=human maxillary poorly differentiated squamous cell carcinoma.Subjects: Male CD-1 (ICR) nu/nu, BALBc nu/nu and conventional C 57 BL/6 N (age 10 weeks, 20-25g body weight).Imidazole compounds: Misonidazole (MISO) 20mg/mouse, dinitroimidazole ethanol (DNIE) 10mg/mouse and 5-methoxy carbonyl-2-methyl sulfinyl-l-methyl imidazole (KIH-3) 40mg/mouse.Tumors were transplanted to the subcutaneous region of the right thigh of CD-1 (ICR) nu/nu.Radiation: 60Co 15 Gy local radiation.These imidazole compounds were administrated into the abdomen of the CD-1 (ICR) nu/nu prior to 30 minutes of local irradiation.NK activity was compared among CD-1 (ICR) nu/nu, BALBc nu/nu and conventionalC 57 BL/6 N.Results: Radiosensitive effect was evaluated for MISO 20mg+60Co 15 Gy group. DNIE 10mg+60Co 15 Gy and KIH-3 40mg+60Co 15 Gy groups were observed to show radioprotective effects rather than radiosensitivity.% NK activity was as follows:CD-1 (ICR) nu/nu, 4.9 in YAC-1 100:1; 7.0 in RL-male 100:1. BALBc nu/nu 24.6 in YAC-1 100:1; 15.9 in RL-male 100:1. C 57 BL/6 N 21.4 in YAC-1 100:1; 24.0 in RL-male 100:1.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Japanese Journal of Oral & Maxillofacial Surgery
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
